Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
167.55
+2.82 (+1.71%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,620,814
Open
164.72
Bid (Size)
164.90 (200)
Ask (Size)
169.50 (100)
Prev. Close
164.73
Today's Range
163.00 - 169.00
52wk Range
110.03 - 169.00
Shares Outstanding
145,800,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Biogen Completes Acquisition of Alcyone Therapeutics
November 14, 2025
From
Biogen Inc.
Via
GlobeNewswire
Explore the top gainers and losers within the S&P500 index in today's session.
↗
November 13, 2025
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday.
Via
Chartmill
Performance
YTD
+11.7%
+11.7%
1 Month
+17.8%
+17.8%
3 Month
+23.3%
+23.3%
6 Month
+29.4%
+29.4%
1 Year
+4.7%
+4.7%
More News
Read More
5 Insightful Analyst Questions From Biogen’s Q3 Earnings Call
November 06, 2025
Via
StockStory
Topics
Earnings
Earnings Scheduled For October 30, 2025
↗
October 30, 2025
Via
Benzinga
Biogen Licenses Vanqua Bio’s Immunology Drug In $1.06B Deal
↗
October 24, 2025
Via
Stocktwits
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
November 03, 2025
From
Biogen Inc.
Via
GlobeNewswire
BIIB Q3 Deep Dive: New Product Launches Offset Guidance Cut, R&D Pipeline Expands
October 31, 2025
Via
StockStory
Biogen (NASDAQ:BIIB) Beats Q3 Sales Expectations
October 30, 2025
Via
StockStory
Topics
Artificial Intelligence
Biogen Sinks Back Into A Buy Zone After Cutting Its Profit Guide
↗
October 30, 2025
Via
Investor's Business Daily
Examining the Future: Biogen's Earnings Outlook
↗
October 29, 2025
Via
Benzinga
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
October 28, 2025
Via
StockStory
Topics
Artificial Intelligence
Biogen's Immunology Pipeline Has Long-Term Potential: Analyst
↗
October 24, 2025
Via
Benzinga
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
October 24, 2025
From
Biogen Inc.
Via
GlobeNewswire
3 Profitable Stocks We Steer Clear Of
October 24, 2025
Via
StockStory
Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
October 22, 2025
From
Biogen Inc.
Via
GlobeNewswire
ARPA-H Taps Former DARPA Innovator to Ignite High-Risk, High-Reward Health Tech Revolution
October 21, 2025
Via
TokenRing AI
Topics
Artificial Intelligence
Intellectual Property
J.L. Bainbridge Exits Most of Biogen Stake as Biotech Stock Eyes Turnaround
↗
October 19, 2025
Via
The Motley Fool
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity
↗
October 16, 2025
Via
Benzinga
3 Reasons BIIB is Risky and 1 Stock to Buy Instead
October 16, 2025
Via
StockStory
Topics
Government
Stocks
World Trade
1 Healthcare Stock to Research Further and 2 We Find Risky
October 14, 2025
Via
StockStory
Topics
Stocks
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
October 13, 2025
From
Biogen Inc.
Via
GlobeNewswire
Reflecting On Therapeutics Stocks’ Q2 Earnings: Amgen (NASDAQ:AMGN)
October 12, 2025
Via
StockStory
Topics
Artificial Intelligence
UnitedHealth, Brookdale, Collegium Pharmaceutical, QuidelOrtho, and Biogen Shares Are Falling, What You Need To Know
October 10, 2025
Via
StockStory
Topics
Economy
Government
World Trade
7 Analysts Have This To Say About Biogen
↗
October 10, 2025
Via
Benzinga
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
October 09, 2025
From
Stoke Therapeutics, Inc.
Via
Business Wire
Frequently Asked Questions
Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 167.55
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 11/14/25 04:00 PM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 24.43B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 24B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.